Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01881932 · ClinicalTrials.gov registry record · NA
Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)
A NA study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT01881932 is a NA study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 19 participants.
The verdict
NCT01881932, a NA study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
In this study the investigators will assess how useful and safe acupuncture is in easing the pain, tingling and numbness that is caused by chemotherapy. The researchers hope this will prevent the need to reduce the amount of chemotherapy a patient receives.
Interventions
- DEVICE Acupuncture using Seirin® needles
- DEVICE Sham Acupuncture using Park Sham placebo acupuncture device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01881932
The ClinicalTrials.gov registry entry for NCT01881932 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acupuncture using Seirin® needles is the first listed.
NCT01881932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01881932 about?
NCT01881932 is a clinical study titled "Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)". In this study the investigators will assess how useful and safe acupuncture is in easing the pain, tingling and numbness that is caused by chemotherapy. The researchers hope this will prevent the need to reduce the amount of chemotherapy a patient receives.
What is the current status of trial NCT01881932?
This trial is currently terminated. It is a NA study. The enrollment target is 19 participants. The study started on 2013-02. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01881932?
The interventions under investigation include: Acupuncture using Seirin® needles (DEVICE), Sham Acupuncture using Park Sham placebo acupuncture device (DEVICE).
Who is sponsoring clinical trial NCT01881932?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.